Breaking News Instant updates and real-time market news.

ORTX

Orchard Therapeutics

$11.94

-0.36 (-2.93%)

07:08
09/30/19
09/30
07:08
09/30/19
07:08

Orchard Therapeutics announces presentation of clinical data for OTL-200

Orchard Therapeutics announced the presentation of new clinical data at the upcoming European Society of Gene & Cell Therapy Annual Congress in Barcelona, Spain, October 22-25, 2019. The poster presentation will highlight initial results from the ongoing clinical trial with a cryopreserved formulation of OTL-200 for metachromatic leukodystrophy that is being conducted at the San Raffaele-Telethon Institute for Gene Therapy in Milan, Italy. Poster presentation details for OTL-200: Lentiviral haematopoietic stem cell gene therapy for metachromatic leukodystrophy: Preliminary results from a clinical trial with a cryopreserved formulation of OTL-200. Metachromatic leukodystrophy is a rare and life-threatening inherited disease of the body's metabolic system occurring in approximately one in every 100,000 live births. MLD is caused by a mutation in the arylsulfatase-A gene that results in the accumulation of sulfatides in the brain and other areas of the body, including the liver, the gallbladder, kidneys, and/or spleen. Over time, the nervous system is damaged and patients with MLD will experience neurological problems such as motor, behavioral and cognitive regression, severe spasticity and seizures, finding it more and more difficult to move, talk, swallow, eat and see. Currently, there are no effective treatments for MLD. In its late infantile form, mortality at 5 years from onset is estimated at 50% and 44% at 10 years for juvenile patients.1 OTL-200 is an ex vivo, autologous, hematopoietic stem cell-based gene therapy being studied for the treatment of MLD.

  • 01

    Oct

  • 02

    Oct

ORTX Orchard Therapeutics
$11.94

-0.36 (-2.93%)

09/05/19
LEHM
09/05/19
INITIATION
Target $21
LEHM
Overweight
Orchard Therapeutics initiated with an Overweight at Barclays
Barclays analyst Gena Wang started Orchard Therapeutics with an Overweight rating and $21 price target. The company's lentiviral gene therapy platform strategically targets genetic diseases that have validated approaches with hematopoietic stem cell transplant, Wang tells investors in a research note. She believes Orchard's three lead assets are "fairly de-risked" with high likelihood of regulatory approvals in 2020 and 2021. Multiple near- and mid-term catalysts make for a favorable risk/reward on the shares, says the analyst.
09/17/19
GUGG
09/17/19
INITIATION
Target $31
GUGG
Buy
Orchard Therapeutics initiated with a Buy at Guggenheim
Guggenheim initiated Orchard Therapeutics with a Buy and $31 price target.
09/17/19
09/17/19
INITIATION
Target $31

Buy
Guggenheim bullish on Orchard Therapeutics, initiates with a Buy
As previously reported, Guggenheim analyst Whitney Ijem started coverage of Orchard Therapeutics with a Buy rating and $31 price target. The analyst likes the company's ex vivo, lentiviral gene therapy platform which is differentiated and de-risked by the sheer amount of positive clinical data that it has generated. Further, he believes its three lead assets could be approved and launched in the next 12-24 months, which will be followed by an earlier stage pipeline that leverages the same platform.
09/17/19
09/17/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Match Group (MTCH) initiated with a Buy at Citi. 2. Restaurant Brands (QSR) initiated with a Buy at Argus. 3. Orchard Therapeutics (ORTX) initiated with a Buy at Guggenheim. 4. Axonics (AXNX) initiated with an Outperform at SVB Leerink. 5. Cellular Biomedicine (CBMG) initiated with a Buy at BTIG. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

MDCO

The Medicines Co.

$58.66

6.74 (12.98%)

, NVS

Novartis

$90.28

0.26 (0.29%)

07:46
11/19/19
11/19
07:46
11/19/19
07:46
Periodicals
Novartis holds talks about potential acquisition of Medicines Co, Bloomberg says »

Medicines Co. (MDCO) has…

MDCO

The Medicines Co.

$58.66

6.74 (12.98%)

NVS

Novartis

$90.28

0.26 (0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

ACHN

Achillion

$6.26

0.005 (0.08%)

07:44
11/19/19
11/19
07:44
11/19/19
07:44
Hot Stocks
Achillion granted EMA PRIME designation for danicopan for PNH treatment »

Achillion Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANET

Arista Networks

$192.91

0.38 (0.20%)

07:43
11/19/19
11/19
07:43
11/19/19
07:43
Initiation
Arista Networks initiated  »

Arista Networks initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 09

    Dec

  • 09

    Dec

MYOV

Myovant Sciences

$6.02

-0.14 (-2.27%)

07:43
11/19/19
11/19
07:43
11/19/19
07:43
Hot Stocks
Myovant Sciences says primary efficacy endpoint met in Phase 3 HERO study »

Myovant Sciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MXL

MaxLinear

$19.84

-0.2 (-1.00%)

07:42
11/19/19
11/19
07:42
11/19/19
07:42
Upgrade
MaxLinear rating change  »

MaxLinear upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTNT

Fortinet

$103.80

2.31 (2.28%)

07:41
11/19/19
11/19
07:41
11/19/19
07:41
Recommendations
Fortinet analyst commentary  »

Fortinet price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 05

    Dec

  • 06

    Dec

  • 09

    Dec

  • 12

    Dec

OPGN

OpGen

$1.11

0.04 (3.76%)

07:41
11/19/19
11/19
07:41
11/19/19
07:41
Hot Stocks
OpGen says products in development to address 'urgent threat' pathogens »

OpGen announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:40
11/19/19
11/19
07:40
11/19/19
07:40
General news
Treasury Market Outlook: trading was pretty quiet overnight »

Treasury Market Outlook:…

FLT

FleetCor

$298.35

1.19 (0.40%)

07:39
11/19/19
11/19
07:39
11/19/19
07:39
Conference/Events
FleetCor management to meet with BTIG »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

PRIM

Primoris

$21.34

-0.31 (-1.43%)

07:38
11/19/19
11/19
07:38
11/19/19
07:38
Hot Stocks
Primoris announces industrial awards valued over $30M »

Primoris Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AFMD

Affimed N.V.

$2.43

-0.045 (-1.82%)

07:37
11/19/19
11/19
07:37
11/19/19
07:37
Hot Stocks
Affimed N.V. expects cash, cash equivalents to fund operations into 4Q21 »

Cash, cash equivalents…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

ECL

Ecolab

$191.28

-0.45 (-0.23%)

07:37
11/19/19
11/19
07:37
11/19/19
07:37
Conference/Events
Ecolab management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

AFMD

Affimed N.V.

$2.43

-0.045 (-1.82%)

07:37
11/19/19
11/19
07:37
11/19/19
07:37
Hot Stocks
Affimed N.V. appoints Cassandra Choe-Juliak as acting CMO »

Affimed announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

AFMD

Affimed N.V.

$2.43

-0.045 (-1.82%)

07:35
11/19/19
11/19
07:35
11/19/19
07:35
Hot Stocks
Affimed N.V. plans preclinical studies for AFM28, AFM32 in 2020 »

Affimed selected two new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

FB

Facebook

$197.45

2.38 (1.22%)

, BMY

Bristol-Myers

$57.62

-0.99 (-1.69%)

07:35
11/19/19
11/19
07:35
11/19/19
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

FB

Facebook

$197.45

2.38 (1.22%)

BMY

Bristol-Myers

$57.62

-0.99 (-1.69%)

LK

Luckin Coffee

$28.17

1.11 (4.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

  • 26

    Nov

PTON

Peloton

$30.22

2.94 (10.78%)

07:34
11/19/19
11/19
07:34
11/19/19
07:34
Recommendations
Peloton analyst commentary  »

JPMorgan reiterates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

MXL

MaxLinear

$19.84

-0.2 (-1.00%)

07:34
11/19/19
11/19
07:34
11/19/19
07:34
Upgrade
MaxLinear rating change  »

MaxLinear upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESL

Esterline

$0.00

(0.00%)

07:34
11/19/19
11/19
07:34
11/19/19
07:34
Conference/Events
Esterline management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AFMD

Affimed N.V.

$2.43

-0.045 (-1.82%)

07:33
11/19/19
11/19
07:33
11/19/19
07:33
Hot Stocks
Affimed N.V. to initiate Phase 1/2a study of AFM24 in 1Q20 »

In October 2019, Affimed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

MBRX

Moleculin Biotech

$1.04

(0.00%)

07:32
11/19/19
11/19
07:32
11/19/19
07:32
Hot Stocks
Moleculin Biotech reports preliminary data from clinical trial of WP1220 »

Moleculin Biotech…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YGYI

Youngevity

07:32
11/19/19
11/19
07:32
11/19/19
07:32
Recommendations
Youngevity analyst commentary  »

Youngevity price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HP

Helmerich & Payne

$38.84

-1.72 (-4.24%)

07:32
11/19/19
11/19
07:32
11/19/19
07:32
Downgrade
Helmerich & Payne rating change  »

Helmerich & Payne…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VTR

Ventas

$58.35

0.1 (0.17%)

07:32
11/19/19
11/19
07:32
11/19/19
07:32
Upgrade
Ventas rating change  »

Ventas upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AFMD

Affimed N.V.

$2.43

-0.045 (-1.82%)

07:32
11/19/19
11/19
07:32
11/19/19
07:32
Earnings
Affimed N.V. reports Q3 EPS (EUR0.17) vs. (EUR0.19) last year »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

PGNY

Progyny

$24.89

1.095 (4.60%)

07:31
11/19/19
11/19
07:31
11/19/19
07:31
Initiation
Progyny initiated  »

Progyny initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.